Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics

Drug Profile

Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics

Alternative Names: Aspirin derivative - Antibe Therapeutics; ATB 340; ATB-282; ATB-284; ATB-352; ATB-427; ATB-428; ATB-429

Latest Information Update: 27 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antibe Therapeutics
  • Class Analgesics; Anti-inflammatories; Anticoagulants; Sulfides
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute pain; Blood coagulation disorders; Inflammatory bowel diseases
  • No development reported Irritable bowel syndrome

Most Recent Events

  • 27 Oct 2016 Antibe Therapeutics plans a preclinical toxicology trial for Acute pain
  • 16 Nov 2015 Hydrogen sulfide-based therapeutics licensed to Knight Therapeutics for commercialisation in Canada, Israel, Romania, Russia and sub-Saharan Africa for the treatment of Pain and Inflammation
  • 20 Jul 2015 Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics is available for licensing as of 20 Jul 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top